RayKnowChina Research Map
Shortlist0

Naval Medical University

海军军医大学

ShanghaiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.08%Leads under 1 in 100 of China's research papers on NPC

Led 2 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyImmunotherapy

Hospitals counted here

  1. Changhai Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.9%Leads under 1 in 100 of China's research papers on ESCC

Led 26 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
1
Research papers it led
26
Trials it led
7
Share of China's trials
1.2%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025
ThemesEarly detection & endoscopyImaging & AIMolecular markers & genomics

Hospitals counted here

  1. Changhai Hospital22
  2. Changzheng Hospital3
  3. First Affiliated Hospital of Naval Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and validation of a multimodal deep learning model for early esophageal squamous neoplasia detection and invasion depth prediction.2026Endoscopy
  2. Accurate Nonendoscopic Detection of Early Esophageal Squamous Malignant Lesions Using Sponge-Based Methylated DNA Biomarkers.2026The American journal of gastroenterology
  3. Gene-specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study.2025Clinical and translational medicineFree full text
  4. Long-term Outcomes of Endoscopic Radiofrequency Ablation versus Endoscopic Submucosal Dissection for Widespread Superficial Esophageal Squamous Cell Neoplasia.2025Gut and liverFree full text
  5. Outcomes of endoscopic submucosal dissection versus esophagectomy for poorly differentiated superficial esophageal squamous cell carcinoma: A 10-year cohort study.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Trials on ClinicalTrials.gov6
  1. Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal NeoplasiaEnrolling by invitationNCT06984055Lead sponsorStart 2025-03
  2. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Study sitePhase 3Start 2019-09
  3. Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell CarcinomaStatus unknownNCT06429865Lead sponsorN/AStart 2024-05
  4. Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell CarcinomaStatus unknownNCT06412419Lead sponsorStart 2024-05
  5. China Early Esophageal Cancer CohortStatus unknownNCT06515964Lead sponsorStart 2022-10
  6. Esophageal cAncer Screening TrialCompletedNCT04609813Lead sponsorStart 2021-01

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
2.0%Leads about 1 in 49 of China's research papers on HCC ▼ from 3.8%

Led 301 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
5
Research papers it led
301
Trials it led
58
Share of China's trials
4.0%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 002025
ThemesRecurrence & prognosisSurgery & liver transplantImaging, AI & early detection

Hospitals counted here

  1. Eastern Hepatobiliary Surgery Hospital214
  2. Changhai Hospital19
  3. Changzheng Hospital15
  4. First Affiliated Hospital of Naval Medical University15
  5. Gongli Hospital Counted in the group total1
  6. Shanghai Gongli Hospital, Second Military Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.2024Nature medicineRCT
  2. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.2023Signal transduction and targeted therapyRCTFree full text
  3. Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial.2023Chinese journal of integrative medicineRCT
  4. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.2022Hepatology internationalRCT
  5. Operator radiation dose during trans-hepatic arterial chemoembolization: different patients' positions via transradial or transfemoral access.2022Diagnostic and interventional radiology (Ankara, Turkey)RCTFree full text
Trials on ClinicalTrials.gov6
  1. A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver CancerNot yet recruitingNCT07337031Lead sponsorN/AStart 2026-01
  2. Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver CancerNot yet recruitingNCT07363356Lead sponsorPhase 2Start 2026-01
  3. The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLDRecruitingNCT07285850Lead sponsorPhase 2/Phase 3Start 2025-10
  4. A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06902389Lead sponsorPhase 1/Phase 2Start 2025-07
  5. A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC PatientsRecruitingNCT06418659Lead sponsorEarly phase 1Start 2024-10
  6. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.6%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 55 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
6
Research papers it led
55
Trials it led
16
Share of China's trials
1.1%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsEarly detection & endoscopy

Hospitals counted here

  1. Changhai Hospital31
  2. Changzheng Hospital17
  3. Eastern Hepatobiliary Surgery Hospital6
  4. First Affiliated Hospital of Naval Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Optical enhancement mode 2 improves the detection rate of gastric neoplastic lesion in high-risk populations: A multicenter randomized controlled clinical study.2024United European gastroenterology journalRCTFree full text
  2. Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with breast, colorectal or gastric cancer under fed condition: A multicentric, randomized, open-label, single-dose, two-period, two2023European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical SciencesRCT
  3. Linked Color Imaging Can Improve Detection Rate of Early Gastric Cancer in a High-Risk Population: A Multi-Center Randomized Controlled Clinical Trial.2021Digestive diseases and sciencesRCT
  4. A Novel Liver Metastasis Score for Patients Undergoing Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: A Multi-institutional Study.2025Annals of surgical oncology
  5. Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer.2025Molecular therapy : the journal of the American Society of Gene TherapyFree full text
Trials on ClinicalTrials.gov6
  1. HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric CancerRecruitingNCT07621484Lead sponsorPhase 2Start 2026-07
  2. Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal LesionsNot yet recruitingNCT07507071Lead sponsorStart 2026-03
  3. Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESDNot yet recruitingNCT07088744Lead sponsorStart 2025-07
  4. Effect of Premedication With Pronase on Mucosal Cleanliness During EGDRecruitingNCT06713421Lead sponsorN/AStart 2024-12
  5. AI-Assisted Non-Contrast CT for Multi-Cancer ScreeningRecruitingNCT06632886Lead sponsorN/AStart 2024-10
  6. Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric CancerRecruitingNCT06346093Lead sponsorN/AStart 2024-04

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Retinoblastoma New since 2021

Led 2 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Changhai Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
4.8%Leads about 1 in 21 of China's research papers on Chordoma ▼ from 6.2%

Led 5 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Changzheng Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.0%Leads under 1 in 100 of China's research papers on Osteosarcoma ▼ from 1.6%

Led 22 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
22
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Changzheng Hospital16
  2. Eastern Hepatobiliary Surgery Hospital4
  3. Changhai Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.1%Leads about 1 in 87 of China's research papers on Gastrointestinal stromal tumour ▼ from 2.4%

Led 6 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Changzheng Hospital4
  2. Changhai Hospital1
  3. Eastern Hepatobiliary Surgery Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.09%Leads under 1 in 100 of China's research papers on Neuroblastoma ▼ from 0.7%

Led 1 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.02%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma ▼ from 3.6%

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Changzheng Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.8%Leads about 1 in 56 of China's research papers on Myeloma

Led 30 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
2
Research papers it led
30
Trials it led
14
Share of China's trials
2.9%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesRelapse & resistanceDiagnosis, MRD & riskDrug combinations

Hospitals counted here

  1. Changzheng Hospital26
  2. Shanghai Gongli Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis 2025Annals of hematologyRCTFree full text
  2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS St2025Annals of hematologyRCTFree full text
  3. B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.2024JAMA oncologyFree full text
  4. Prognostic significance of hematological parameters and albumin in BCMA-targeted CAR-T therapy for multiple myeloma.2025Frontiers in immunologyFree full text
  5. GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.2025The Lancet. Haematology
Trials on ClinicalTrials.gov6
  1. Study of CT071 Injection in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT06407947Lead sponsorEarly phase 1Start 2024-06
  2. a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Lead sponsorEarly phase 1Start 2024-12
  3. KPD Consolidation After ASCT in NDMM PatientsRecruitingNCT06879379Study sitePhase 2/Phase 3Start 2025-03
  4. To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLRecruitingNCT06045091Study siteEarly phase 1Start 2023-07
  5. Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MMRecruitingNCT05594797Study sitePhase 2Start 2022-07
  6. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
0.8%Leads under 1 in 100 of China's research papers on IgG4-RD

Led 2 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
2
Share of China's trials
4.7%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025
ThemesKidney, retroperitoneum & vesselsTreatment & relapseDiagnosis & look-alikes

Hospitals counted here

  1. First Affiliated Hospital of Naval Medical University1
  2. Changzheng Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.4%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 4 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 002025

Hospitals counted here

  1. Changzheng Hospital2
  2. Changhai Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.8%Leads under 1 in 100 of China's research papers on IgA nephropathy New since 2021

Led 6 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. Changzheng Hospital5
  2. Changhai Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
2.0%Leads about 1 in 50 of China's research papers on Osteogenesis imperfecta ▼ from 4.6%

Led 2 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Changzheng Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis ▼ from 2.0%

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Changhai Hospital1
  2. Changzheng Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
1.7%Leads about 1 in 59 of China's research papers on Familial adenomatous polyposis ▼ from 3.9%

Led 1 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
33.3%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Changzheng Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer.2023Cancer research and treatment
Trials on ClinicalTrials.gov1
  1. Colorectal Adenoma Canceration in FAPNot yet recruitingNCT04531930Lead sponsorStart 2020-10

PubMed searchClinicalTrials.gov